What is Immunome's interest income (expense), operating?

Immunome (IMNM) reported interest income (expense), operating of $5.49M in Q1 2026.

How has Immunome's interest income (expense), operating changed year-over-year?

Immunome's interest income (expense), operating increased by 83.3% year-over-year, from $3M to $5.49M.

What is the long-term trend for Immunome's interest income (expense), operating?

Over 4 years (2021 to 2025), Immunome's interest income (expense), operating has grown at a 485.1% compound annual growth rate (CAGR), from -$10K to $11.72M.

Immunome IMNM Interest Income (Expense), Operating

Interest Income (Expense), Operating at other companies

BeldenBDC

-$13.46M-33.2%

DoubleVerify HoldingsDV

-$273K+8.7%

Freeport-McMoRan Inc.FCX

-$114M-62.9%

Empire PetroleumEP

-$430M+4.7%

Baker HughesBKR

-$86M-68.6%

SyscoSYY

-$168M-12.8%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.24B+323%

Enterprise value$1.66B+470%

P/S557.1×+509×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's interest income (expense), operating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's interest income (expense), operating?: Immunome (IMNM) reported interest income (expense), operating of $5.49M in Q1 2026.
How has Immunome's interest income (expense), operating changed year-over-year?: Immunome's interest income (expense), operating increased by 83.3% year-over-year, from $3M to $5.49M.
What is the long-term trend for Immunome's interest income (expense), operating?: Over 4 years (2021 to 2025), Immunome's interest income (expense), operating has grown at a 485.1% compound annual growth rate (CAGR), from -$10K to $11.72M.